藉新型微脂體LPPC包覆P4N並結合寡醣標靶分子 評估肝癌的化學治療效率

Abstract

肝癌由於檢查和診斷上的困難，通常在最後都導致腫瘤的轉移。此外現今並沒有一個有效的抗癌藥物能夠提升肝癌腫瘤轉移患者的存活率。因此在本研究裡我們試著結合LPPC/P4N/BSA-TriGalNAc作為一個具療效的複合體，而此複合體與P4N單獨施用比較，對肝癌細胞株生長展現了較佳的抑制力。另外在細胞及動物實驗當中都驗證了，BSA-TriGalNAc能專一性地將微脂複合體傳遞到有表現Ashwell-Morell受器的肝癌細胞株(HepG2細胞)。然而在動物實驗中，吸附BSA-TriGalNA的LPPC/P4N於腫瘤治療上造成多種正常組織的損傷。這些結果顯示了LPPC/P4N複合體也許在惡化的肝癌上提供了一個可行性的治療策略。

Usually, hepatocellular carcinoma (HCC) is a malignant tumor due to its poor surveillance and diagnosis, which eventually results in metastasis. In addition, there are no effective anticancer drugs could provide a better survival benefit to metastatic HCC patients, currently. Thus, in this study, we attempted to combine the LPPC/P4N/BSA-TriGalNAc as an efficient therapeutic complex, and this complex showed a potent proliferative inhibition of HCC cells than free P4N treatment. In addition, in vitro and in vivo studies both proved that the BSA-TriGalNAc could specifically deliver the lipoplex to the Ashwell-Morell receptor (AMR) positive HCC cell (HepG2 cell). However, in xenograft animal model, LPPC/P4N/BSA-TriGalNAc treatment revealed several damages in normal tissues. These results indicated that the LPPC/P4N complex may supply a feasible strategy for the advanced liver cancer therapy.